Molecular diagnostic tests involve analyzing the DNA, RNA or proteins of an organism to identify molecular signatures of disease (biomarkers) or to evaluate the predisposition of an individual for a disease. The results of these tests influence clinical decision-making so assuring their sensitivity and specificity is of utmost importance. Current Protocols and Thermo Scientific NanoDrop Products are pleased to present a FREE 1-hr webinar by two leaders in molecular diagnostic test development.
Dr. Joshua LaBaer, Director of the Piper Center for Personalized Diagnostics at the Biodesign Institute at ASU, will describe the approach to developing molecular diagnostics tests, their applications, their relative strengths and shortcomings, how to select appropriate methods or combinations of methods for particular research problems, and critical aspects of test performance and validation.
Dr. Wayne Grody, Director of the Diagnostic Molecular Pathology Laboratory at the UCLA Medical Center, will then describe some examples of translation of molecular diagnostic methods from the bench to the clinic, including the critical issues of quality assurance, ethical controversies, and regulatory compliance in testing for both common and ultra-rare (“orphan”) diseases.
What you will learn:
•Strengths and weaknesses of various molecular diagnostic methods
•How to select appropriate methods and combinations of methods for a particular problem
•About controls and how to evaluate the reliability of molecular diagnostic assay results
•About the contrasting challenges of analytic vs. clinical validation of new tests
•About critical regulatory and ethical aspects of clinical molecular diagnostics testing
Comments are closed.